Pfizer has recently announced plans to advance its weight-loss pill, danuglipron, following positive results from an early-stage study. The pharmaceutical company is aiming to compete in the lucrative market for obesity drugs currently dominated by Eli Lilly and Novo Nordisk. Pfizer's danuglipron is a once-a-day oral treatment that the company believes has the potential for a competitive edge within the GLP-1 drug space. With a robust pipeline of clinical candidates, Pfizer is conducting further tests to determine the ideal dosage for the drug. Analysts from Morgan Stanley predict that the global obesity drug market could reach over $100 billion by 2030, with potential for even higher sales as the use of these drugs expands beyond weight-loss to treating other diseases. Pfizer's focus on developing danuglipron could help the company recover profits lost from declining demand for its COVID-19 products, Comirnaty and Paxlovid.